A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT06255977
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT06255977
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06255977. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2024-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- CN-105
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- SDM Bio Service Inc.
Record details
- Record id
cardio:ct-nct06255977- Content hash
4d25f2ecfb3258d0ab7702d42fefa6dc43ae03dd2c0e198b47549462c4cded3b